Oral delivery of peptides: opportunities and issues for translation

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 193-195

  Brayden, David J ^a   Alonso, Maria Jose ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b University of Santiago de Compostela ^*  (Spain)

Author keywords

anti diabetic peptides; intestinal permeation enhancers; nanocarriers; nanomedicines; nanotoxicology; oral peptide delivery

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DESMOPRESSIN; EDETIC ACID; EMULSIFYING AGENT; INSULIN; LIPID EMULSION; LIPOSOME; MELITTIN; NANOCAPSULE; NANOPARTICLE; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PENETRATIN; DRUG; PEPTIDE;

CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EDITORIAL; HUMAN; MICROSCOPY; MOLECULAR WEIGHT; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE; MACROMOLECULE;

DRUG DELIVERY SYSTEMS; MACROMOLECULAR SUBSTANCES; PEPTIDES; PHARMACEUTICAL PREPARATIONS;

EID: 84996553525     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.10.005     Document Type: Editorial

References (20)

1. [1] Moroz, E., Matoori S, S., Leroux, J.C., Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101:101 (2016), 108–121, 10.1016/j.addr.2016.01.010.
2. [2] Windsor, E., Cronheim, G.E., Gastrointestinal absorption of heparin and synthetic heparinoids. Nature 4772 (1961), 263–264.
3. [3] Damgé, C., Michel, C., Aprahamianm, M., Couvreur, P., New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37 (1988), 246–251.
4. [4] Aguirre, T.A., Teijeiro-Osorio, D., Rosa, M., Coulter, I.S., Alonso, M.J., Brayden, D.J., Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106 (2016), 223–241.
5. [5] Fouché, M., Schäfer, M., Berghausen, J., Desrayaud, S., Blatter, M., Piéchon, P., Dix, I., Martin Garcia, A., Roth, H.J., Design and development of a cyclic decapeptide scaffold with suitable properties for bioavailability and oral exposure. ChemMedChem 11 (2016), 1048–1059, 10.1002/cmdc.201600082.
6. [6] Buckley, S.T., Hubalek, F., Rahbek, U.L., Chemically-modified peptides and proteins - critical considerations for oral delivery. Tissue Barriers, 4, 2016 (KTIB #1156805).
7. [7] Matsson, P., Doak, B., Over, K., Cell permeability beyond the rule of 5. Adv. Drug Deliv. Rev. 101 (2016), 42–61.
8. [8] Melmed, S., New therapeutic agents for acromegaly. Nat. Rev. Endocrinol. 12 (2016), 90–98, 10.1038/nrendo.2015.196.
9. th , 2016.
10. [10] Lakkireddy, H.R., Urmann, M., Besenius, M., Werner, U., Haack, T., Brun, P., Alié, J., Illel, B., Hortala, L., Vogel, R., Bazile, D., Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv. Drug Deliv. Rev. 106 (2016), 196–222.
11. [11] Beloqui, A., Rieux A, A.d., Préat, V., Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier. Adv. Drug Deliv. Rev. 106 (2016), 242–255.
12. [12] Lundquist, P., Artursson, P., Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv. Drug Deliv. Rev. 106 (2016), 256–276.
13. [13] Uhlén, M., Fagerberg, B.L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. Proteomics. Tissue-based map of the human proteome. Science, 347, 2015, 1260419.
14. [14] Maher, S., Mrsny, R.M., Brayden, D.J., Intestinal permeation enhancers for oral peptide delivery. Adv. Drug Deliv. Rev. 106 (2016), 277–319.
15. [15] Malhaire, H., Gimel, J.C., Roger, E., Benoît, J.P., Lagarce, F., How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?. Adv. Drug Deliv. Rev. 106 (2016), 320–336.
16. [16] Niu, Z., Conejos-Sánchez, I., Griffin, B.T., O'Driscoll, C.M., Alonso, M.J., Lipid-based nanocarriers for oral peptide delivery. Adv. Drug Deliv. Rev. 106 (2016), 337–354.
17. [17] Sánchez-Navarro, M., Garcia, J., Giralt, E., Teixidó, M., Using peptides to increase transport across the intestinal barrier. Adv. Drug Deliv. Rev. 106 (2016), 355–366.
18. [18] Griffin, B.T., Guo, J., Presas, E., Donovan, M., Alonso, M.J., O'Driscoll, C.M.C., Pharmacokinetic, pharmacodynamics and biodistributon following oral administration of nanocarriers containing peptide and protein drugs. Adv. Drug Deliv. Rev. 106 (2016), 367–380.
19. [19] Ciappellano, S.G., Tedesco, E., Venturini, M., Benetti, F., In vitro toxicity assessment of oral nanocarriers. Adv. Drug Deliv. Rev. 106 (2016), 381–401.
20. [20] Őrfi, E., Szebeni, J., The immune system of the gut and potential adverse effects of oral nanocarriers on its function. Adv. Drug Deliv. Rev. 106 (2016), 402–409.